Pipeline, page-7

There is a massive pipe-line of R&D and product development across applications I have never heard of before (drug delivery).

The drug delivery device PNV is developing deserves attention, imo.

With the proviso that most “market research” reports need to be taken with a rather large grain of salt, these excerpts below, which have been drawn from from two different reports on the implantable drug eluting device market, provide a glimpse into the potential of this particular market.

• Growing incidence of chronic diseases, coupled with rising demand for minimally invasive treatment options, is driving the market for implantable drug delivery devices.
• Implantable drug-eluting devices provide localized and site-specific drug delivery which is especially important in applications such as oncology, cardiology, and opioid addiction treatment.
• These devices assure improved patient compliance that has been one of the longstanding challenges for healthcare providers.
• Bioresorbable drug eluting devices have emerged as the fourth revolution in interventional cardiology owing to potential advantages.
• Contraceptive drug-eluting devices currently account for 2/5th share in the global market revenue.
• Advent of biodegradable implants enables targeted delivery of chemotherapeutics to tumor cells without damaging normal cells.
• Autoimmune diseases….are expected to exhibit the fastest CAGR owing to rising prevalence of multiple sclerosis and rheumatoid arthritis.
• The demand for biodegradable drug-eluting stents is expected to climb in the near future…
• The global implantable drug-eluting devices market is expected to surpass the US$ 10 Bn mark by 2019 end.
• The global implantable drug delivery devices market size is expected to reach USD 31.6 billion by 2025, registering a 7.5% CAGR during the forecast period.

https://www.futuremarketinsights.com/reports/implantable-drug-eluting-devices-market

https://www.prnewswire.com/news-rel...arket-2018---forecast-to-2025--300702024.html